Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani
Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/
Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire)
After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe Kiani with the deepest respect from the global community of families, experts, policymakers, and politicians in patient safety who have greatly benefited from his unwavering commitment to reducing avoidable harm to zero. His partnership with the World Health Organization, his contribution to the Global Patient Safety Action Plan, his outstanding leadership over many years at the Global Ministerial Summits on Patient Safety, and his drive and determination to ensure the ongoing advancement of science and technology across the global medical devices industries have ensured that our patients at every level and in every setting continue to benefit from his latest advances to reduce avoidable harm. The healthcare world is a safer environment because of his dedication, and both patients and healthcare workers will continue to reap the benefits of his excellence for decades to come.”
“I’m honored,” stated Joe Kiani. “The Patient Safety Global Ministerial Summit, the World Health Organization, and Dr. Tedros Adhanom Ghebreyesus have played a leading role in making patient safety a priority around the world. I believe that if we all work together, we have the tools and know-how to create a safer healthcare system for all. To get to zero, we have to implement evidence-based practices, and we need our board members and hospital C-suites demanding their implementation. There is great momentum, and we cannot stop until we reach ZERO preventable harm in our hospitals.”
Since their inception in 2016, the Global Ministerial Summits on Patient Safety have succeeded in raising awareness, as well as creating and sustaining the momentum of the global patient safety movement, as evidenced by the adoption of the WHA resolution (WHA72.6) “Global Action on Patient Safety” in May 2019, which enabled the first-ever World Patient Safety Day in September 2019.
Some of the world’s most prominent leaders in patient safety are presenting at the PSMF’s Summit this year, including Dr. Don Berwick, Senior Fellow at the Institute for Healthcare Improvements. In his keynote, Berwick will discuss how to ensure progress on improvements in patient safety remain at the forefront of the national conversation following last year’s recommendations to the US president in the PCAST report, “A Transformational Effort on Patient Safety.”
During the afternoon session, Dr. Craig Umscheid, Director of the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality (AHRQ), will speak on AHRQ’s National Action Alliance for Patient and Workforce Safety, which takes a systems approach informed by safety self-assessments to improve patient and workforce safety across all healthcare delivery settings, with a goal of reducing harms by 50% from the pandemic peak in two years.
In her keynote, Dr. Michelle Schreiber, Director of Quality Measurement & Value Based Incentives Group, Center for Medicare and Medicaid Services (CMS), will detail the eight goals of CMS’s National Quality Strategy and outline CMS’s efforts to improve healthcare for all by promoting transparency and a safety culture through partnerships, while incentivizing zero harm.
The Summit’s first day will also include presentations from Dr. Diana Ramos, the Surgeon General of California; Dr. Peter Ziese, Head of Medical Innovation & Strategy at PHILIPS; Scott Hamilton Kennedy, an Academy Award-nominated documentary filmmaker; Dr. Evan Benjamin, Associate Professor of Medicine at Harvard Medical School; and Henrietta Hughes, the Patient Safety Commissioner for England.
Panel discussions will focus on advancements in using real-time data from electronic medical records, improving safety through systemwide collaboration, and the essential role hospital boards and the C-suite can play in fostering a culture of safety.
PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906604830/en/
Contacts
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release
With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom